EP Wealth Advisors LLC Sells 1,675 Shares of Humana Inc. (NYSE:HUM)

EP Wealth Advisors LLC trimmed its position in Humana Inc. (NYSE:HUMFree Report) by 72.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 636 shares of the insurance provider’s stock after selling 1,675 shares during the period. EP Wealth Advisors LLC’s holdings in Humana were worth $201,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in HUM. CarsonAllaria Wealth Management Ltd. increased its holdings in shares of Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares in the last quarter. Creative Financial Designs Inc. ADV increased its stake in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. Atwood & Palmer Inc. acquired a new position in Humana during the third quarter worth $29,000. Hantz Financial Services Inc. bought a new position in shares of Humana in the second quarter valued at $35,000. Finally, Family Firm Inc. acquired a new position in shares of Humana during the second quarter valued at about $37,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Up 0.5 %

Shares of NYSE HUM opened at $274.12 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $33.01 billion, a PE ratio of 24.28, a P/E/G ratio of 2.15 and a beta of 0.53. Humana Inc. has a one year low of $213.31 and a one year high of $486.00. The business’s fifty day moving average price is $274.13 and its 200-day moving average price is $324.53.

Humana (NYSE:HUMGet Free Report) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, equities research analysts anticipate that Humana Inc. will post 16.14 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.29%. Humana’s payout ratio is 31.36%.

Wall Street Analysts Forecast Growth

HUM has been the topic of several recent research reports. UBS Group dropped their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and raised their target price for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Piper Sandler cut Humana from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $392.00 to $274.00 in a research note on Thursday, October 3rd. Finally, Barclays upped their target price on shares of Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $304.15.

Get Our Latest Stock Report on HUM

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.